Related Experiment Video
Updated: Jun 25, 2026

Modifying Levels of Maternal Dietary Folic Acid or Choline to Study the Impact of Deficiencies on Offspring Health Outcomes
Published on: June 28, 2024
Association Between MTHFR Gene Polymorphisms and Subclinical Hypothyroidism in Early Pregnancy: A Retrospective
Liyang Liu1, Cheng Wang1, Xia Chen1
1Department of Obstetrics and Gynecology, Affiliated Hospital of Jiangnan University, Wuxi, 214000, People's Republic of China.
The methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism is linked to subclinical hypothyroidism in early pregnancy. Abnormal pre-pregnancy BMI and anemia history also increase subclinical hypothyroidism risk.
Area of Science:
- Genetics
- Obstetrics
- Endocrinology
Background:
- Subclinical hypothyroidism (SCH) in early pregnancy poses risks to both mother and fetus.
- Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms are implicated in various pregnancy complications.
- Understanding the genetic factors associated with SCH is crucial for early detection and management.
Purpose of the Study:
- To investigate the association between MTHFR gene polymorphisms (C677T and A1298C) and SCH in pregnant women.
- To identify other potential risk factors for SCH in early pregnancy.
Main Methods:
- A retrospective case-control study involving 100 pregnant women with SCH and 300 controls.
- MTHFR C677T and A1298C polymorphisms analyzed using PCR-RFLP.
- Thyroid function tests (TSH, FT3, FT4) and logistic regression analysis performed.
Main Results:
- The MTHFR C677T polymorphism showed a significant association with SCH (P<0.05).
- The C677T T allele, abnormal pre-pregnancy BMI, and anemia history were identified as risk factors for SCH.
- No significant association was found for the MTHFR A1298C polymorphism.
Conclusions:
- MTHFR C677T polymorphism is a potential risk factor for SCH in early pregnancy.
- Abnormal pre-pregnancy BMI and anemia history are also associated with increased SCH risk.
- Further prospective studies are needed to confirm these findings and guide clinical practice.
Related Concept Videos
Hypothyroidism II: Pathophysiology
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Graves' Disease I: Introduction
